Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.73
CUR's Cash to Debt is ranked higher than
66% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CUR: 4.73 )
CUR' s 10-Year Cash to Debt Range
Min: 1.47   Max: No Debt
Current: 4.73

Equity to Asset 0.75
CUR's Equity to Asset is ranked higher than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CUR: 0.75 )
CUR' s 10-Year Equity to Asset Range
Min: -0.81   Max: 0.93
Current: 0.75

-0.81
0.93
F-Score: 4
Z-Score: 12.11
M-Score: -10.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11385.45
CUR's Operating margin (%) is ranked lower than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CUR: -11385.45 )
CUR' s 10-Year Operating margin (%) Range
Min: -11385.45   Max: -507.12
Current: -11385.45

-11385.45
-507.12
Net-margin (%) -18029.09
CUR's Net-margin (%) is ranked lower than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CUR: -18029.09 )
CUR' s 10-Year Net-margin (%) Range
Min: -18029.09   Max: -534.63
Current: -18029.09

-18029.09
-534.63
ROE (%) -235.59
CUR's ROE (%) is ranked higher than
50% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CUR: -235.59 )
CUR' s 10-Year ROE (%) Range
Min: -754.16   Max: -90.67
Current: -235.59

-754.16
-90.67
ROA (%) -102.15
CUR's ROA (%) is ranked higher than
52% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CUR: -102.15 )
CUR' s 10-Year ROA (%) Range
Min: -1813.79   Max: -78.89
Current: -102.15

-1813.79
-78.89
ROC (Joel Greenblatt) (%) -5421.65
CUR's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CUR: -5421.65 )
CUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9581.82   Max: -1662.3
Current: -5421.65

-9581.82
-1662.3
Revenue Growth (%) -100.00
CUR's Revenue Growth (%) is ranked higher than
50% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CUR: -100.00 )
CUR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 26
Current: -100

0
26
EBITDA Growth (%) -10.60
CUR's EBITDA Growth (%) is ranked higher than
74% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CUR: -10.60 )
CUR' s 10-Year EBITDA Growth (%) Range
Min: -17.2   Max: 35.7
Current: -10.6

-17.2
35.7
EPS Growth (%) -13.70
CUR's EPS Growth (%) is ranked higher than
73% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CUR: -13.70 )
CUR' s 10-Year EPS Growth (%) Range
Min: -40.6   Max: 32.2
Current: -13.7

-40.6
32.2
» CUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CUR Guru Trades in

CUR Guru Trades in

CUR Guru Trades in

Q1 2014

CUR Guru Trades in Q1 2014

George Soros 191,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-03-31 New Buy0.01%$2.91 - $4.61 $ 3.03-14%191600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.50
CUR's P/B is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CUR: 9.50 )
CUR' s 10-Year P/B Range
Min: 3.91   Max: 150.33
Current: 9.5

3.91
150.33
P/S 9802.00
CUR's P/S is ranked lower than
55% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CUR: 9802.00 )
CUR' s 10-Year P/S Range
Min: 0   Max: 451
Current: 9802

0
451
EV-to-EBIT -17.08
CUR's EV-to-EBIT is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CUR: -17.08 )
CUR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -17.08

Current Ratio 7.30
CUR's Current Ratio is ranked higher than
84% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CUR: 7.30 )
CUR' s 10-Year Current Ratio Range
Min: 0.52   Max: 16.97
Current: 7.3

0.52
16.97
Quick Ratio 7.30
CUR's Quick Ratio is ranked higher than
85% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CUR: 7.30 )
CUR' s 10-Year Quick Ratio Range
Min: 0.52   Max: 16.97
Current: 7.3

0.52
16.97

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.80
CUR's Price/Net Cash is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. CUR: 10.80 )
CUR' s 10-Year Price/Net Cash Range
Min: 7.79   Max: 60
Current: 10.8

7.79
60
Price/Net Current Asset Value 10.80
CUR's Price/Net Current Asset Value is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. CUR: 10.80 )
CUR' s 10-Year Price/Net Current Asset Value Range
Min: 7.79   Max: 60
Current: 10.8

7.79
60
Price/Tangible Book 10.10
CUR's Price/Tangible Book is ranked higher than
67% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CUR: 10.10 )
CUR' s 10-Year Price/Tangible Book Range
Min: 7.4   Max: 60
Current: 10.1

7.4
60
Price/Median PS Value 2.80
CUR's Price/Median PS Value is ranked higher than
55% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CUR: 2.80 )
CUR' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 2.68
Current: 2.8

0.47
2.68
Forward Rate of Return (Yacktman) -16.71
CUR's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CUR: -16.71 )
CUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -16.71

-156.4
-21.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7NS.Germany
Neuralstem, Inc. was incorporated in 1997 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is development stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with major research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative conditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company's competitors include major multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.
» More Articles for CUR

Headlines

Articles On GuruFocus.com
Neuralstem Inc. Reports Operating Results (10-Q) Nov 15 2010 
View on CUR Sep 11 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 16 2010 
Neuralstem Inc. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buys Highlight: Neuralstem Inc., Converted Organics Inc., Princeton National Bancorp Inc. Jan 09 2010 
Weekly CEO Buy Highlights: Helix Energy Solutions Group Inc, Neuralstem Inc, Saul Centers Inc, Casua Jan 09 2010 
Weekly CFO Buy Highlights: Neuralstem Inc., New Generation Biofuels Holdings, Converted Organics, Or Jan 04 2010 
Neuralstem Inc. Reports Operating Results (10-Q) Nov 16 2009 
Neuralstem Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 30 2014
Neuralstem Added To Russell 3000 Index Jun 30 2014
Neuralstem, Inc. (CUR): NSI-189: What You Need To Know Jun 26 2014
An Early Valuation Of Neuralstem's NSI-189 For MDD Jun 26 2014
Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder Jun 25 2014
Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress Jun 19 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events Jun 18 2014
Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical... Jun 18 2014
Neuralstem, Inc. – "The FDA is Not the Enemy" Jun 09 2014
Neuralstem, Inc. – "Most men would rather deny a hard truth than face it" May 28 2014
Neuralstem NSI-189 Abstract Teases At Potential Greatness May 28 2014
Neuralstem price target raised to $6 from $4.50 at Aegis May 27 2014
NEURALSTEM, INC. Files SEC form 8-K, Other Events May 23 2014
Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical... May 23 2014
NEURALSTEM, INC. Financials May 16 2014
Neuralstem CEO, Richard Garr, to Present at World Stem Cells & Regenerative Medicine Congress and... May 16 2014
NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... May 12 2014
Neuralstem reports Q1 EPS (7c), one estimate (6c) May 12 2014
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update May 12 2014
NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report May 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide